121 related articles for article (PubMed ID: 38604794)
21. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
Tang HKK; Fung CY; Morgan GJ; Kumar S; Siu L; Ip HWA; Yip SF; Lau KNH; Lau CK; Lee H; Leung KH; Kho B; Wong H; Ngai C; Hwang YY; Sim J; Kwong YL; Chim CS
Ther Adv Hematol; 2022; 13():20406207221082043. PubMed ID: 35465644
[TBL] [Abstract][Full Text] [Related]
22. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
Yang P; Chen H; Liang X; Xu W; Yu S; Huang W; Yi X; Guo Q; Tian M; Yue T; Li M; Zhang Y; Zhang M; Yan Y; Hu Z; Kumar SK; Zhou F; Dai Y; Jin F
Am J Hematol; 2023 Feb; 98(2):251-263. PubMed ID: 36309982
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Pasvolsky O; Ghanem S; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Aljawai Y; Khan HN; Kebriaei P; Lee HC; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 Jan; 14(1):4. PubMed ID: 38199987
[TBL] [Abstract][Full Text] [Related]
24. The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.
Chen Q; Han X; Zheng G; Yang Y; Li Y; Zhang E; Yang L; Dong M; He D; He J; Cai Z
Front Oncol; 2022; 12():1084683. PubMed ID: 36605445
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma].
Liu S; Shang J; Lin Y; Wang ZH; Wei TN; Lin L; Yang T; Chen WM
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1209-1214. PubMed ID: 34794226
[No Abstract] [Full Text] [Related]
26. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Guo W; Zhan A; Mery DE; Munshi MN; Makhoul O; Baily C; Zangari M; Tricot G; Peng H; Shaughnessy JD
Blood Adv; 2023 Nov; 7(21):6676-6684. PubMed ID: 37756524
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
29. [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].
Zhang FJ; Zhou X; Liu SZ; Liu SJ; Liu Y; Zhuang JL
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):673-680. PubMed ID: 37263950
[No Abstract] [Full Text] [Related]
30. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
[TBL] [Abstract][Full Text] [Related]
31. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
[No Abstract] [Full Text] [Related]
33. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
34. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic Value of R-ISS Staging Combined with "Multiple-Hits" in Patients with Multiple Myeloma].
Sun HM; Zhai SS; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):158-166. PubMed ID: 33554813
[TBL] [Abstract][Full Text] [Related]
36. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
38. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
39. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X; Yan W; Mery D; Liu J; Fan H; Xu J; Xu Y; Sui W; Deng S; Zou D; Du C; Yi S; van Rhee F; Barlogie B; Shaughnessy JD; Anderson KC; Zhan F; Qiu L; An G
Am J Hematol; 2024 Apr; 99(4):523-533. PubMed ID: 38247315
[TBL] [Abstract][Full Text] [Related]
40. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
